Non-alcoholic fatty liver disease (metabolic associated fatty liver disease)
Conditions
Interventions
Non-alcoholic fatty liver disease (metabolic associated fatty liver disease) group:None
Sponsors
The First Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. MAFLD Group Inclusion Criteria: Based on histological (liver biopsy), imaging, and blood biomarker evidence of hepatic fat accumulation (hepatic steatosis), with the concomitant presence of any one of the following three conditions: overweight/obesity, type 2 diabetes, or metabolic dysfunction. Metabolic dysfunction is defined as the presence of at least two metabolic risk factors. 2. Healthy Control Group Inclusion Criteria: (1) Fatty liver excluded by abdominal two-dimensional gray-scale ultrasound; (2) No history of hypertension, diabetes, dyslipidemia, coronary heart disease, cerebral infarction, or family history of related diseases; no history of medication for related conditions; no history of alcohol consumption; (3) Body Mass Index (BMI) < 23 kg/m^2; (4) Waist circumference: < 90 cm for males and < 80 cm for females; (5) Average of three blood pressure readings taken on non-consecutive days: 120 mmHg < systolic < 139 mmHg, and 60 mmHg < diastolic < 89 mmHg; (6) Fasting venous plasma glucose =5.6 mmol/L and 2-hour venous plasma glucose <7.8 mmol/L after 75g oral glucose tolerance test; (7) Liver function (ALT, AST) and kidney function (BUN, CREA) within normal ranges; (8) Fasting serum uric acid <420 µmol/L on two non-consecutive days (adults, regardless of gender); (9) Serum triglycerides (TG) <1.70 mmol/L.
Exclusion criteria
Exclusion criteria: 1. Exclusion Criteria for the MAFLD Group (1) History of chronic excessive alcohol consumption: Daily ethanol intake >=30 g/day for males, >= 20 g/day for females. Ethanol intake (g) = Volume (ml) × Alcohol content × 0.8; (2) Presence of other diseases causing elevated liver enzymes: autoimmune liver disease, viral hepatitis, drug-induced liver disease, Wilson's disease, a-1 antitrypsin deficiency, and other chronic liver diseases; liver space-occupying lesions, biliary tract infection or obstruction, etc. (3) Concurrent systemic diseases: total parenteral nutrition, celiac disease, hyperthyroidism or hypothyroidism, Cushing's syndrome, acromegaly, anterior pituitary insufficiency, hypogonadism, etc. (4) History of using or current use of glucocorticoids, sex hormones, amiodarone, sodium valproate, or other medications affecting insulin secretion or insulin sensitivity. (5) History of COVID-19 infection or prior confirmed diagnosis. 2. Exclusion Criteria for Healthy Control Group (1) History of hypertension, any type of diabetes, dyslipidemia, or related medication use; (2) History of parenteral nutrition within 1 month before or during the study period, or use of medications potentially affecting glucose metabolism (e.g., glucocorticoids, thyroxine, thiazide diuretics); (3) History of severe kidney disease or abnormal renal function (serum creatinine >=115 µmol/L); (4) History of malignant tumors or severe psychiatric disorders; (5) Subjects unable to cooperate with the study or unable to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peripheral blood mononuclear cell(PBMC);Peripheral blood mononuclear cell protein;Peripheral blood mononuclear cell RNA; | — |
Secondary
| Measure | Time frame |
|---|---|
| Demographic characteristics (gender, age, height, weight, smoking history, alcohol consumption history [with detailed recording of alcohol content], past medical history, medication history, family history);Glucose metabolism indicators (blood glucose, insulin, C-peptide);Levels of lipid metabolism indicators (TC, TG, HDL-c, LDL-c);Abdominal two-dimensional grayscale ultrasound (evaluating hepatic parenchyma and vascular echogenicity, liver morphology, structural characteristics, and vascular distribution);Abdominal liver fibrosis scan;Liver function (ALT, AST, ?-GGT, ALP, TBIL, DBIL, IBIL);Renal function (CREA, BUN, UA);Platelet levels in complete blood count (CBC); | — |
Countries
China
Contacts
Public ContactXu Yushan
The First Affiliated Hospital of Kunming Medical University
Outcome results
None listed